You are leaving GSKSource to visit a separate website not associated with GSKSource, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Source.GSK is not responsible for content on third-party websites.
CloseX
REQUEST UPDATES
Sign up below to receive the latest news and announcements.
You must fill in all information in order to register.
Thank you! You are now signed up for updates.
Subscription has been already done for this user.
You must fill in all information in order to register.
BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine
The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals
Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
Vaccination with BEXSERO may not result in protection in all vaccine recipients